-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, GRAIL, a company dedicated to the development of early cancer blood tests, announced the launch of a multi-cancer early screening blood test called Galleri, which can be used as a prescription test in the United States to screen high-risk groups
.
At this year's ASCO annual meeting, the company also announced the first results of Galleri's interventional PATHFINDER study
.
Cancer is one of the leading causes of death in the world, and one of the important reasons is that most cancers are already at an advanced stage when they are discovered, and the prognosis of patients is poor
.
Although early cancer screening tests can help detect cancer as early as possible and save patients' lives, there are currently only five cancer types in the United States that have recommended early screening tests
.
Galleri detects the free DNA in the blood and finds the special DNA methylation marks of cancerous cells
.
In previous observational studies, Galleri demonstrated the ability to detect more than 50 cancer types
.
When cancer is found, Galleri can determine the origin of the cancer with high accuracy
.
At this year's ASCO annual meeting, GRAIL announced the first batch of results obtained by Galleri in the interventional study PATHFINDER
.
In this study, 6629 individuals aged 50 years or older underwent Galleri testing.
These people represent a group at higher risk of developing cancer, but there are no obvious signs of cancer before being tested
.
Doctors and patients choose the next step of diagnosis and/or treatment based on the results of Galleri's test
.
PATHFINDER research aims to simulate the application scenarios of Galleri in the real world
.
An interim analysis of the data showed that the early version of Galleri accurately detected 13 cancer types: including breast cancer, colorectal cancer, head and neck cancer, liver cancer and cholangiocarcinoma, lung cancer, lymphocytic leukemia, lymphoma, ovarian cancer, and pancreatic cancer.
, Plasma cell tumors, prostate cancer, small bowel cancer, and Waldenstrom's macroglobulinemia
.
Among the 23 newly discovered cancer patients, nearly 40% (9/23) of the patients' cancer is still in the local stage (stage I-II), and more than half of the patients (13/23) have no distant metastasis (I -Phase III)
.
▲Cancer information of cancer patients detected by Galleri test (picture source: reference [2]) PATHFINDER's mid-term results show that Galleri's positive predictive value (PPV), that is, individuals with positive Galleri test results are subsequently diagnosed with cancer The ratio is 44.
6% (95% CI: 33.
2-56.
7%)
.
Among confirmed cancer patients, Galleri's test results can predict the origin of cancer with 96.
3% accuracy
.
PATHFINDER participants will be followed for 12 months, and the final results are expected to be available in the first half of 2022
.
"Detecting cancer earlier and making treatment more likely to be successful is one of the most significant opportunities for us to reduce the burden of cancer," said Dr.
Joshua Ofman, Chief Medical Officer and Head of External Affairs at GRAIL.
Some screening tests are used together on a large scale, Galleri may have a profound impact on the detection of cancer and ultimately on public health
.
"Reference: [1] GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test.
Retrieved June 7, 2021, from https://grail.
com/press-releases /grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/[2] Interim Results of PATHFINDER, a Clinical Use Study Using a Methylation-Based Multi‑Cancer Early Detection Test.
https://grail.
com/wp-content/uploads/2021/06/ASCO-2021-Pathfinder-Beer_FINAL-for-upload.
pdf Note: This article is intended to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
At this year's ASCO annual meeting, the company also announced the first results of Galleri's interventional PATHFINDER study
.
Cancer is one of the leading causes of death in the world, and one of the important reasons is that most cancers are already at an advanced stage when they are discovered, and the prognosis of patients is poor
.
Although early cancer screening tests can help detect cancer as early as possible and save patients' lives, there are currently only five cancer types in the United States that have recommended early screening tests
.
Galleri detects the free DNA in the blood and finds the special DNA methylation marks of cancerous cells
.
In previous observational studies, Galleri demonstrated the ability to detect more than 50 cancer types
.
When cancer is found, Galleri can determine the origin of the cancer with high accuracy
.
At this year's ASCO annual meeting, GRAIL announced the first batch of results obtained by Galleri in the interventional study PATHFINDER
.
In this study, 6629 individuals aged 50 years or older underwent Galleri testing.
These people represent a group at higher risk of developing cancer, but there are no obvious signs of cancer before being tested
.
Doctors and patients choose the next step of diagnosis and/or treatment based on the results of Galleri's test
.
PATHFINDER research aims to simulate the application scenarios of Galleri in the real world
.
An interim analysis of the data showed that the early version of Galleri accurately detected 13 cancer types: including breast cancer, colorectal cancer, head and neck cancer, liver cancer and cholangiocarcinoma, lung cancer, lymphocytic leukemia, lymphoma, ovarian cancer, and pancreatic cancer.
, Plasma cell tumors, prostate cancer, small bowel cancer, and Waldenstrom's macroglobulinemia
.
Among the 23 newly discovered cancer patients, nearly 40% (9/23) of the patients' cancer is still in the local stage (stage I-II), and more than half of the patients (13/23) have no distant metastasis (I -Phase III)
.
▲Cancer information of cancer patients detected by Galleri test (picture source: reference [2]) PATHFINDER's mid-term results show that Galleri's positive predictive value (PPV), that is, individuals with positive Galleri test results are subsequently diagnosed with cancer The ratio is 44.
6% (95% CI: 33.
2-56.
7%)
.
Among confirmed cancer patients, Galleri's test results can predict the origin of cancer with 96.
3% accuracy
.
PATHFINDER participants will be followed for 12 months, and the final results are expected to be available in the first half of 2022
.
"Detecting cancer earlier and making treatment more likely to be successful is one of the most significant opportunities for us to reduce the burden of cancer," said Dr.
Joshua Ofman, Chief Medical Officer and Head of External Affairs at GRAIL.
Some screening tests are used together on a large scale, Galleri may have a profound impact on the detection of cancer and ultimately on public health
.
"Reference: [1] GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test.
Retrieved June 7, 2021, from https://grail.
com/press-releases /grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/[2] Interim Results of PATHFINDER, a Clinical Use Study Using a Methylation-Based Multi‑Cancer Early Detection Test.
https://grail.
com/wp-content/uploads/2021/06/ASCO-2021-Pathfinder-Beer_FINAL-for-upload.
pdf Note: This article is intended to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
